2023
The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment
O'Shea J, Fanfair R, Williams T, Khalil G, Brady K, DeMaria A, Villanueva M, Randall L, Jenkins H, Altice F, Camp N, Lucas C, Buchelli M, Samandari T, Weidle P. The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 93: 134-142. PMID: 36812382, PMCID: PMC10962216, DOI: 10.1097/qai.0000000000003178.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsFemaleHIV InfectionsHumansMassachusettsParturitionPregnancyProspective StudiesViral LoadConceptsDurable viral suppressionActive public health interventionProportion of PWHPublic health interventionsViral loadCare strategiesHealth interventionsLast viral loadCopies/mLStandard of careRace/ethnicityCare armHIV careViral suppressionAntiretroviral adherenceCD4 categoryExposure categoriesCare individualsPWHCareAge categoriesInterventionTrialsBirth sexRe-Engagement
2021
National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States
Werbel WA, Brown DM, Kusemiju OT, Doby BL, Seaman SM, Redd AD, Eby Y, Fernandez RE, Desai NM, Miller J, Bismut GA, Kirby CS, Schmidt HA, Clarke WA, Seisa M, Petropoulos CJ, Quinn TC, Florman SS, Huprikar S, Rana MM, Friedman-Moraco RJ, Mehta AK, Stock PG, Price JC, Stosor V, Mehta SG, Gilbert AJ, Elias N, Morris MI, Mehta SA, Small CB, Haidar G, Malinis M, Husson JS, Pereira MR, Gupta G, Hand J, Kirchner VA, Agarwal A, Aslam S, Blumberg EA, Wolfe CR, Myer K, Wood RP, Neidlinger N, Strell S, Shuck M, Wilkins H, Wadsworth M, Motter JD, Odim J, Segev DL, Durand CM, Tobian AAR, Piquant D, Link K, Hemmersbach-Miller M, Pearson T, Turgeon N, Lyon G, Kitchens W, Huckaby J, Lasseter A, Elbein R, Roberson A, Ferry E, Klock E, Cochran W, Morrison M, Rasmussen S, Bollinger J, Sugarman J, Smith A, Thomas M, Coakley M, Timpone J, Stucke A, Haydel B, Dieter R, Klein E, Neumann H, Gallon L, Goudy L, Callegari M, Marrazzo I, Jackson T, Pruett T, Farnsworth M, Locke J, Mompoint-Williams D, Basinger K, Mekeel K, Nguyen P, Kwan J, Srisengfa T, Chin-Hong P, Rogers R, Simkins J, Munoz C, Dunn T, Sawinski D, Silveira F, Hughes K, Pakstis D, Nagy J, Baldecchi M, Muthukumar T, Eddie M, Robb K, Salsgiver E, Witting B, Azar M, Villanueva M, Formica R, Tomlin R. National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States. Clinical Infectious Diseases 2021, 74: 2010-2019. PMID: 34453519, PMCID: PMC9187316, DOI: 10.1093/cid/ciab743.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsHIVHIV InfectionsHIV SeropositivityHumansIntegrasesProspective StudiesTissue DonorsUnited StatesViral LoadConceptsHuman immunodeficiency virusDrug resistance mutationsHIV-positive donorsHIV drug resistance mutationsViral loadMedian CD4 T-cell countCD4 T-cell percentagesHIV Organ Policy Equity (HOPE) ActCD4 T-cell countNonnucleoside reverse transcriptase inhibitorIntegrase strand transfer inhibitorsDonor-derived infectionInhibitor-based regimensT cell percentageT-cell countsHepatitis C viremiaHIV viral loadCD4 T cellsDeceased organ donorsReverse transcriptase inhibitorFalse-positive test resultsStrand transfer inhibitorsC viremiaVirologic characteristicsClinical characteristics
2018
“No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder
Oldfield BJ, Muñoz N, Boshnack N, Leavitt R, McGovern MP, Villanueva M, Tetrault JM, Edelman E. “No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder. Journal Of Substance Use And Addiction Treatment 2018, 97: 28-40. PMID: 30577897, DOI: 10.1016/j.jsat.2018.11.007.Peer-Reviewed Original ResearchConceptsOpioid use disorderIntegration of HIVUse disordersClinical staffCare of HIVCommunity-based participatory research principlesBehavioral health integrationImproved patient outcomesEvidence-based treatmentsDiverse care settingsParticipatory research principlesPrimary carePatient outcomesPatient-centered policiesCare settingsHealth integrationHIVQualitative studyStages of changeClinic leadershipCare instrumentIntegrated carePatientsBehavioral healthMeasures of quality
2016
Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation
Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. International Journal Of STD & AIDS 2016, 28: 447-458. PMID: 27193421, DOI: 10.1177/0956462416651528.Peer-Reviewed Original ResearchConceptsInhibitor-based regimensRenal transplantationHIV/AIDSAntiretroviral regimenAntiretroviral therapyGraft survivalHIV-positive renal transplant recipientsEnd-stage renal diseaseHIV-positive patientsRenal transplant recipientsChronic kidney diseaseThree-year survivalInhibitor-based therapyNon-nucleoside reverseDrug-drug interactionsTransferase inhibitorsImmunosuppressive medicationsKidney transplantationTransplant recipientsAllograft rejectionGraft failureRenal diseaseCalcineurin inhibitorsClinical outcomesImmunosuppressive drugs